BridgeBio Oncology Therapeutics, Inc. (NASDAQ:BBOT) has 66 institutional investors with active 13F positions as of March 2026.
| Owner Name | Date | Shares Held | Change (QoQ) | Change (%) | Value (USD) |
|---|---|---|---|---|---|
| Cormorant Asset Management, LP | 31 Mar, 2026 | 17,878,594 | 0 | 0.00% | $160,013,416.00 |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 31 Mar, 2026 | 4,885,446 | 0 | 0.00% | $43,724,742.00 |
| Omega Fund Management, LLC | 31 Mar, 2026 | 3,289,661 | 0 | 0.00% | $29,442,466.00 |
| EcoR1 Capital, LLC | 31 Mar, 2026 | 2,823,126 | 0 | 0.00% | $25,266,978.00 |
| Alphabet Inc. | 31 Mar, 2026 | 2,823,126 | 0 | 0.00% | $25,266,978.00 |
| WELLINGTON MANAGEMENT GROUP LLP | 31 Mar, 2026 | 2,818,348 | -88,655 | -3.05% | $25,224,215.00 |
| Enavate Sciences GP, LLC | 31 Mar, 2026 | 2,626,946 | 0 | 0.00% | $23,511,167.00 |
| CITADEL ADVISORS LLC | 31 Mar, 2026 | 2,528,762 | -1,562 | -0.06% | $22,632,420.00 |
| Novo Holdings A/S | 31 Mar, 2026 | 2,185,923 | 224,606 | 11.45% | $19,564,011.00 |
| BlackRock, Inc. | 31 Mar, 2026 | 2,088,297 | 3,460 | 0.17% | $18,690,258.00 |
| Laurion Capital Management LP | 31 Mar, 2026 | 1,922,656 | -1,007,220 | -34.38% | $17,207,771.00 |
| ARMISTICE CAPITAL, LLC | 31 Mar, 2026 | 1,328,000 | 328,000 | 32.80% | $11,885,600.00 |
| Aisling Capital Management LP | 31 Mar, 2026 | 1,018,018 | 453,393 | 80.30% | $9,111,261.00 |
| Paradigm Biocapital Advisors LP | 31 Mar, 2026 | 868,213 | -1,393,536 | -61.61% | $7,770,506.00 |
| Octagon Capital Advisors LP | 31 Mar, 2026 | 719,000 | -324,110 | -31.07% | $6,435,050.00 |
| ROYCE & ASSOCIATES LP | 31 Mar, 2026 | 636,522 | 636,522 | 0.00% | $5,696,872.00 |
| GEODE CAPITAL MANAGEMENT, LLC | 31 Mar, 2026 | 579,234 | 17,247 | 3.07% | $5,186,709.00 |
| EVENTIDE ASSET MANAGEMENT, LLC | 31 Mar, 2026 | 541,181 | -541,181 | -50.00% | $4,697,451.00 |
| VANGUARD CAPITAL MANAGEMENT LLC | 31 Mar, 2026 | 538,441 | 538,441 | 0.00% | $4,819,047.00 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 31 Mar, 2026 | 437,889 | 437,889 | 0.00% | $3,920.00 |